# Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

> **NCT05632562** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 20 (estimated)

## Conditions studied

- High Grade Glioma

## Interventions

- **DRUG:** O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI

## Key facts

- **NCT ID:** NCT05632562
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-07
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05632562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05632562, "Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05632562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*